Argenx Takes Slow But Steady Approach To Vyvgart Sales

Amid Pandemic-Related And Educational Blocks

Despite a US approval for its novel FcRn inhibitor Vyvgart in gMG, the firm has realistic expectations of sales, factoring in concerns about COVID-19 and lagging medical education.  

Blocks with shopping trolleys representing sales
Vyvgart Sales May Not Be As High As Rival Soliris Off The Bat • Source: Alamy

argenx N.V. is having to take a gradual approach to growing Vyvgart sales as the generalized myasthenia gravis (gMG) product faces hurdles from the COVID-19 pandemic and the lack of medical education on the drug’s target, FcRn.

The US Food and Drug Administration gave Vyvgart (efgartigimod alfa-fcab) the green light on 17 December on the back of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip